viruslik
particl
vlp
mimic
whole
construct
viru
particl
devoid
viral
genom
use
subunit
vaccin
design
vlp
elicit
effici
protect
immun
direct
immunogen
compar
solubl
antigen
coadminist
adjuv
sever
booster
inject
sever
prokaryot
eukaryot
system
insect
yeast
plant
e
coli
use
express
recombin
protein
especi
vlp
product
recent
studi
also
gener
vlp
plant
use
differ
transient
express
vector
edibl
vaccin
vlp
viral
particl
appli
differ
function
gene
therapi
vaccin
nanotechnolog
diagnost
herein
describ
vlp
product
differ
system
well
applic
biolog
medicin
v
c
wiley
period
inc
biopolym
v
iruslik
particl
vlp
known
viral
empti
shell
maintain
structur
properti
virion
without
genom
construct
consid
effici
vaccin
platform
therapeut
deliveri
system
mani
antigen
readili
display
surfac
vlp
antigen
genet
chemic
fuse
vlp
regard
report
immun
stimul
vlp
contain
stimul
innat
immun
tlr
pattern
recognit
receptor
prr
due
express
multival
structur
b
induct
strong
humor
respons
also
igm
tcell
independ
way
c
enhanc
uptak
process
present
apc
mhc
mhc
ii
crosspresent
pathway
due
particul
natur
vlp
vlp
subcutan
intramuscularli
inject
small
diamet
facilit
entri
lymphat
vessel
direct
drainag
local
lymph
node
lymph
node
vlp
taken
lymph
node
resid
dendrit
cell
dc
uptak
enhanc
size
form
vlp
vlp
stimul
cell
via
mhc
ii
pathway
well
highli
effici
crosspresent
mhc
class
pathway
gener
virallik
particl
consid
vaccin
candid
natur
properti
multimer
antigen
specif
structur
suitabl
stimul
effici
humor
cellular
immun
current
develop
recombin
subunit
vaccin
suv
significantli
increas
use
heterolog
express
system
antigen
deriv
mani
bacteri
viral
fungal
parasit
pathogen
use
safe
effect
vaccin
five
vlpbase
vaccin
alreadi
approv
includ
three
hbv
two
hpv
veterinari
field
vlpbase
vaccin
porcin
circoviru
type
approv
vlpbase
vaccin
target
human
anim
diseas
recent
late
stage
clinic
trial
vlp
posit
valu
academ
industri
commerci
system
especi
gene
therapi
design
nanomateri
howev
studi
vlpbase
applic
vaccin
gene
drug
deliveri
imag
must
follow
show
reliabl
cost
effici
technolog
furthermor
express
system
would
improv
achiev
best
strategi
vlp
product
differ
viral
gene
review
focu
vlp
characterist
applic
especi
vaccin
deliveri
system
dna
sirna
drug
note
vaccin
field
whenev
virallik
particl
carri
genet
materi
call
vector
vaccin
gene
therapi
call
viral
vector
howev
simplic
review
call
particl
entitl
virallik
particl
vlp
virallik
particl
vlp
gener
thirti
variou
infecti
virus
anim
human
vlp
compos
one
structur
capsid
protein
possess
natur
properti
selfassembl
morpholog
similar
authent
virus
compar
live
virus
vlp
nonrepl
noninfect
due
lack
infecti
genet
materi
viruslik
particl
potenti
use
safe
vaccin
candid
without
need
adjuv
differ
virus
present
differ
structur
gener
virallik
particl
simpl
viral
capsid
one
two
major
protein
eg
parvovirus
papillomavirus
circovirs
calcivirus
hepat
e
viru
hev
polyomavirus
b
complex
viral
capsid
variou
protein
layer
encod
mani
distinct
mrna
gener
singl
polyprotein
eg
picornavirus
c
viral
capsid
lipid
envelop
includ
lipid
bilay
obtain
host
cell
well
viral
glycoprotein
spike
eg
influenza
hiv
hepat
c
figur
show
gener
model
vlp
along
applic
select
express
vector
one
major
factor
vlp
gener
report
show
success
product
vlp
indic
bacteri
system
yeast
insect
system
use
case
addit
mammalian
cell
plant
usual
appli
produc
vlp
special
properti
bacteri
system
often
includ
commerci
ecoli
strain
express
vector
produc
nonenvelop
vlp
high
level
compar
system
tabl
addit
bacteri
cell
appli
gener
vlp
need
sever
type
structur
protein
avibirnaviru
ibdv
report
indic
express
hepat
b
viru
hbv
capsid
protein
e
coli
lead
format
structur
similar
hbv
core
hbc
particl
bacteri
figur
gener
model
vlp
along
applic
pictur
show
recombin
pentam
assembl
vitro
capsidlik
structur
selfassembl
recombin
viral
coat
protein
empti
capsid
promis
strategi
product
viruslik
particl
vlp
vaccin
design
result
vlp
induc
protect
immun
respons
mimick
authent
epitop
virion
system
alway
desir
plan
vlp
product
due
sever
factor
lack
abil
gener
recombin
protein
mammalianlik
posttransl
modif
ptm
b
failur
produc
correct
disulfid
bond
c
drawback
protein
solubl
exist
lipopolysaccharid
lp
endotoxin
product
recombin
protein
rp
viral
coat
protein
cp
effici
produc
insolubl
inclus
bodi
purifi
denatur
condit
refold
selfassembl
indic
parvoviru
ccmv
cmv
plant
virus
simpl
chang
cultiv
condit
lowtemperatur
solv
problem
inclus
bodi
induc
format
solubl
vlp
perform
two
viral
system
densoviru
ihhnv
potyviru
pvi
factor
includ
resist
marker
express
plasmid
composit
cultiv
medium
also
chang
vlp
assembl
eg
bacteriophag
qb
anoth
strategi
appli
increas
express
level
solubl
involv
use
differ
fusion
protein
system
eg
glutathionestransferas
gst
fusion
protein
papillomaviru
polyomaviru
mupyv
picornaviru
fmdv
prokaryot
host
recent
use
gener
vlp
eg
lactobacillu
intracellular
assembl
vlp
report
lactobacillu
casei
lactoseinduc
express
strain
furthermor
product
vlp
use
lactobacillu
develop
new
live
mucos
prophylact
vaccin
tabl
pseudomona
fluorescen
p
fluorescen
express
system
effici
choic
e
coli
simpl
manipul
high
yield
activ
solubl
protein
largescal
cultiv
differ
p
fluorescen
e
coli
includ
variou
size
genom
divers
metabol
approach
influenc
gener
recombin
protein
capsid
protein
plant
bromoviru
cowpea
chlorot
mottl
viru
ccmv
recent
express
solubl
form
p
fluorescen
assembl
vlp
vivo
construct
structur
similar
natur
viral
particl
provid
plant
eukaryot
express
system
strike
altern
bacteria
especi
solv
problem
bacteri
endotoxin
vaccin
develop
structur
gene
mammalian
virus
express
yeast
abl
form
vlp
express
host
effici
appli
gener
first
licens
hbv
vaccin
hbsag
one
antigen
commonli
util
product
vlpbase
hbv
vaccin
hbsag
express
pichia
pastori
p
pastori
saccharomyc
cerevisia
cerevisia
hansenula
polymorpha
h
polymorpha
tabl
critic
consid
virallik
particl
alway
form
cultiv
procedur
yeast
cell
studi
show
selfassembl
vlp
pichia
system
complet
protein
purif
express
selfassembl
recombin
bacteriophag
q
coat
protein
qcp
indic
saccharomyc
cerevisia
pichia
pastori
yeastderiv
qvlp
greatli
immunogen
mous
similar
ecolideriv
qvlp
vlp
produc
saccharomyc
cerevisia
could
packag
function
heterolog
mrna
exampl
linkag
packag
sequenc
human
growth
hormon
mrna
allow
packag
mrna
vlp
inde
high
stabil
vlp
suggest
effici
deliveri
system
rnabas
vaccin
p
pastori
system
also
util
potent
altern
express
ccmv
coat
protein
vlp
due
easi
manipul
high
express
level
addit
system
util
express
effici
premembran
envelop
glycoprotein
dengu
viru
type
hbsag
hccag
result
gener
vlp
major
advantag
yeast
system
ptm
includ
phosphoryl
glycosyl
indic
hbv
vlp
studi
indic
hbc
phosphoryl
play
major
role
viral
replic
capsid
format
yeastderiv
hbc
vlp
valuabl
vaccin
diagnost
furthermor
potent
multigen
express
system
construct
yeast
exampl
express
three
rotaviru
structur
gene
singl
plasmid
vector
led
gener
tripl
layer
vlp
saccharomyc
cerevisia
howev
multimer
protein
vlp
support
envelop
virus
eg
gag
vlp
suggest
yeast
essenti
factor
host
thu
gener
envelop
vlp
perform
use
cerevisia
spheroplast
morpholog
similar
immatur
viral
particl
gener
construct
yeast
express
system
especi
hansenula
pichia
strain
difficult
bacteri
vector
addit
yield
vlp
product
less
ecoli
limit
yeast
system
dissimilar
mammalian
cell
ptm
protein
especi
glycosyl
therefor
system
suitabl
gener
nonenvelop
virallik
particl
anoth
attract
system
util
broadli
product
vlp
baculovirusinsect
cell
express
system
due
shirbaghae
bolhassani
advantag
rapid
growth
ratio
cultur
prepar
largescal
ptm
target
protein
similar
mammalian
cell
result
show
yeast
insect
cell
previous
use
express
sever
polyomavirus
assembl
virallik
particl
addit
insect
cell
use
provid
vlpbase
vaccin
eg
approv
hpv
vaccin
cervarix
inde
insect
cell
abl
gener
vlp
type
ie
envelop
nonenvelop
envelop
vlp
clinic
trial
main
limit
insect
cell
system
protein
contamin
envelop
baculoviru
particl
suggest
develop
effici
plan
purif
vlp
recent
coexpress
four
gene
human
influenza
viru
ie
ha
na
insect
cell
led
gener
influenza
vlp
protect
mice
viru
challeng
data
suggest
virallik
particl
hope
vaccin
candid
influenza
probabl
subtyp
virul
avian
influenza
virus
noninfecti
virallik
particl
alphaviru
sav
also
gener
use
recombin
baculovirus
express
sav
capsid
protein
two
major
immunodomin
viral
glycoprotein
insect
cell
moreov
baculoviru
express
system
util
gener
vlp
cowpea
mosaic
viru
cpmv
tomato
bushi
stunt
viru
recent
nonrepl
baculoviru
develop
cope
problem
baculoviru
contamin
stabl
system
use
insect
cell
also
test
moreov
silkworm
express
system
effici
appli
gener
vlp
surfac
vlp
could
chang
strategi
irrespect
construct
envelop
silkworm
show
high
capabl
product
recombin
protein
comparison
insect
cell
also
easi
inexpens
protein
prepar
similar
ecoli
express
system
two
decad
differ
mammalian
cell
line
develop
sourc
commerci
therapeut
protein
clinic
applic
abil
proper
protein
fold
assembl
ptm
eg
correct
glycosyl
pattern
howev
high
cost
product
potenti
safeti
concern
remain
challeng
system
mammalian
cell
progress
util
produc
vlpbase
vaccin
eg
influenza
virus
instanc
gener
stabl
mammalian
cell
line
eg
vero
cell
express
four
influenza
structur
protein
ha
na
matrix
led
form
hybrid
vlp
contain
matrix
protein
surfac
glycoprotein
influenza
type
respect
anoth
exampl
produc
vlp
cell
hbv
vlp
cho
cell
plant
system
plant
success
use
express
specif
gene
product
feasibl
recombin
plant
gener
vaccin
antigen
shown
tobacco
plant
potato
tuber
other
approach
develop
vaccin
strategi
stimul
mucos
well
system
immun
respons
addit
deliv
oral
part
normal
biolog
function
human
antigen
express
plant
system
show
extens
disulphid
crosslink
oligomer
format
viruslik
particl
exampl
hepat
b
major
surfac
antigen
express
sever
plant
system
plant
abl
express
assembl
type
vlp
ie
envelop
nonenvelop
multimer
chimer
protein
high
express
vlp
plant
easi
rapid
eg
week
use
tobacco
mosaic
viru
tmv
rna
replicon
system
andor
bean
yellow
dwarf
viru
beydv
dna
replicon
system
anoth
advantag
plant
use
plant
viru
particl
deliveri
system
present
foreign
epitop
furthermor
problem
plantspecif
glycan
partial
solv
use
develop
transgen
plant
human
glycosyl
pathway
plantderiv
vlp
use
oral
deliveri
vaccin
virallik
particl
resist
digest
enzym
solubl
protein
bodi
highli
order
pack
structur
exampl
gastrointestin
virusesderiv
vlp
includ
norovirus
rotavirus
util
oral
potent
candid
mucos
immun
plantderiv
vlp
show
structur
vlp
gener
express
system
accompani
compar
higher
immunogen
plantderiv
vlp
could
induc
protect
humor
cellular
immun
also
safeti
clinic
studi
show
level
protein
express
recombin
plant
variabl
often
low
therefor
increas
express
necessari
practic
effici
product
recent
progress
glycoengin
plant
allow
humanlik
glycolmodif
optim
desir
glycan
structur
increas
safeti
function
recombin
pharmaceut
glycoprotein
plantbas
system
stabil
antigen
thu
reduc
storag
distribut
cost
differ
applic
viruslik
particl
toxoplasma
gondii
gondii
oblig
intracellular
parasit
infect
nucleat
cell
warmblood
vertebr
parasit
abl
stimul
strong
humor
cellular
mucos
immun
thu
use
effici
deliveri
system
heterolog
antigen
gondii
appli
vector
live
vaccin
infecti
pathogen
recent
nonpathogen
kinetoplastida
leishmania
tarentola
util
express
heterolog
protein
studi
show
express
mammalian
glycoprotein
parasit
lead
modif
mammalianlik
oligosaccharid
recent
group
focus
use
live
vector
kill
vaccin
also
gener
viral
coat
protein
assembl
vlp
system
viruslik
particl
show
effici
strategi
deliv
antigen
immun
system
induc
arm
adapt
immun
inde
vlp
present
antigen
epitop
proper
conform
lead
induc
humor
respons
exampl
preclin
trial
influenza
vlp
indic
capac
induc
humor
cellular
immun
respons
low
antigen
dose
sever
author
report
antibodi
respons
parenter
oral
administ
plantderiv
antigen
exogen
antigen
vlp
taken
profession
antigen
present
cell
apc
especi
dc
follow
antigen
process
present
via
mhc
class
ii
molecul
dc
activ
matur
upregul
costimulatori
molecul
cytokin
product
stimul
helper
cell
event
effici
induc
humor
cellular
immun
addit
exogen
vlp
enter
cytosol
dc
process
present
mhc
class
molecul
cytotox
lymphocyt
ctl
use
crosspresent
furthermor
bcell
activ
use
vlp
robust
enough
induc
cellindepend
igm
antibodi
dc
load
yeastderiv
hiv
vlp
alter
gagspecif
memori
cell
effector
cell
crosspresent
chronic
hivinfect
individu
although
gagspecif
cell
patient
show
respons
report
show
express
system
use
gener
vlp
might
significantli
affect
direct
type
outcom
immun
respons
exampl
potent
specif
immunomodulatori
effect
assign
yeastderiv
hiv
vlp
comparison
express
system
hand
plantor
insectderiv
vlp
consist
capsid
protein
hpv
immuno
genic
equal
degre
half
mice
fed
transgen
potato
express
hpv
vlp
develop
antibodi
studi
indic
vlp
taken
clathrindepend
macropinocytosi
phagocytosi
degrad
acid
lysosom
compart
vlpderiv
peptid
load
onto
mhc
recycl
cell
surfac
studi
show
uptak
activ
dc
vlp
involv
proteoglycan
receptor
nfkb
inhibit
heparin
sever
data
suggest
differ
rout
vlp
uptak
dc
langerhan
cell
lc
exampl
lc
dc
intern
similar
amount
hpvvlp
vaccin
design
albeit
differ
uptak
mechan
vlp
uptak
dc
result
activ
crosspresent
mhc
irestrict
peptid
costimul
tcell
hand
vlp
uptak
lc
lead
crosspresent
absenc
costimul
effici
vlp
crosspresent
lc
costimul
achiev
addit
ligand
lack
protect
immun
respons
viral
contact
lc
may
explain
women
fail
induc
immun
respons
viru
lc
endocytos
hpv
vlp
via
nonclathrin
noncaveola
actinindepend
pathway
wherea
dc
take
hpv
vlp
clathrinmedi
mechan
via
macropinocytosi
actindepend
manner
differ
endocytosi
result
process
present
hpv
vlp
peptid
lc
similar
dc
surfac
absenc
costimul
addit
lc
incub
hpv
vlp
gener
effici
amount
proinflammatori
cytokin
could
stimul
hpvspecif
immun
respons
incub
cell
despit
differ
vlp
taken
dc
lc
abl
prime
naiv
cell
induc
cytolyt
effector
cell
vitro
furthermor
gag
viruslik
particl
could
stimul
strong
humor
cellular
immun
respons
vlp
express
recombin
baculovirus
activ
human
pbmc
releas
proinflammatori
tnfa
antiinflammatori
ifnc
cytokin
well
gmcsf
doseand
timedepend
manner
furthermor
vlpinduc
monocyt
activ
shown
upregul
molecul
involv
antigen
present
mhc
ii
cell
adhes
exposur
vlp
serum
inactiv
capac
stimul
cytokin
product
link
vlp
adjuv
molecul
also
shown
improv
immunogen
nanobioparticl
adjuv
vlp
eg
cpg
poli
c
adjuv
elicit
higher
titer
total
specif
igg
compar
vlp
alon
furthermor
vlp
alon
induc
balanc
pattern
vlp
formul
adjuv
elicit
igg
subclass
poli
c
potent
cpg
shirbaghae
bolhassani
anim
model
addit
mice
immun
chimer
simian
immunodefici
viru
siv
vlp
contain
gmcsf
significantli
induc
siv
envspecif
antibodi
well
neutral
activ
higher
level
elicit
standard
siv
vlp
siv
vlp
contain
standard
vlp
mix
solubl
gmcsf
hand
incorpor
immunostimulatori
molecul
show
significantli
increas
tcell
respons
siv
env
compar
standard
siv
vlp
formul
vlp
rough
lp
rlp
adjuv
well
dna
primedvlp
boost
regimen
led
increas
specif
immun
respons
compar
vlp
alon
among
vlprlp
highli
enhanc
immun
respons
recent
studi
demonstr
potenti
hbc
vlp
oral
immunogen
intraperiton
immun
hbc
vlp
induc
strong
mix
respons
contrast
oral
administr
hbc
vlp
gener
high
humor
respons
mainli
antibodi
direct
toward
respons
essenti
control
intracellular
pathogen
addit
intranas
monoval
adjuv
norwalk
vlp
vaccin
well
toler
highli
immunogen
studi
show
chimer
hpvvlp
abl
elicit
potent
ctl
respons
mice
tumor
howev
mechan
cell
prime
remain
obscur
hpv
vlp
could
bind
human
mhc
class
iiposit
apc
interact
fccriii
immatur
dc
activ
incub
hpv
vlp
shown
bind
uptak
vlp
dc
fccrii
fccriii
fccriiiii
defici
mice
reduc
compar
wildtyp
mice
addit
matur
murin
dc
fccriiiiidefici
mice
vlp
also
reduc
indic
dc
matur
thu
ag
present
diminish
absenc
express
fccr
poor
immunogen
mucos
administ
protein
major
barrier
develop
effici
oral
vaccin
one
way
overcom
obstacl
use
appropri
adjuv
also
deliveri
antigen
mucos
surfac
vlp
provid
effici
way
induc
mucos
immun
oral
intranas
immun
norwalk
vlp
rotaviru
vlp
without
adjuv
intestin
iga
detect
immun
mice
protect
viru
challeng
addit
plasma
cell
precursor
migrat
genit
tract
deriv
primarili
mucos
lymphoid
tissu
often
secret
iga
studi
indic
immun
respons
gener
mucos
administr
vlp
gener
weaker
system
administr
vlp
specif
iga
higher
intestin
wash
follow
intrarect
ir
intravagin
iva
immun
higher
vagin
wash
follow
intramuscularli
im
ir
iva
immun
studi
suggest
immunogen
viru
particl
mucos
surfac
probabl
properti
particul
antigen
assembl
multim
subunit
inde
vlp
might
activ
taken
mucos
apc
integrin
receptor
lipoparticl
stabl
highli
purifi
homogen
special
vlp
contain
high
concentr
integr
membran
protein
integr
membran
protein
involv
differ
biolog
function
target
exist
therapeut
drug
howev
hydrophob
domain
membran
protein
difficult
manipul
outsid
live
cell
lipoparticl
incorpor
wide
varieti
membran
protein
includ
g
proteincoupl
receptor
ion
channel
viral
envelop
lipoparticl
provid
platform
differ
applic
antibodi
screen
product
immunogen
ligand
bind
assay
assembl
envelop
virus
lipid
order
domain
host
cell
plasma
membran
known
lipid
raft
frequent
function
natur
target
viral
protein
role
lipid
raft
organ
complex
combin
immun
receptor
antigen
present
cell
signal
extens
recogn
hand
order
improv
immunogen
envelop
glycoprotein
fusion
perform
carrier
protein
hepat
b
surfac
antigen
hbsag
capabl
spontan
assembl
viruslik
particl
hybrid
protein
assembl
effici
nm
particl
particl
resembl
nativ
hbsag
particl
size
densiti
consist
lipid
composit
content
per
particl
particul
fold
nativ
conform
biolog
activ
shown
high
affin
bind
particl
lipoprotein
micel
array
surfac
close
mimic
surfac
virion
particl
enhanc
qualiti
also
quantiti
antibodi
elicit
vaccin
viruslik
particl
show
expand
spectrum
applic
gene
therapi
nanotechnolog
vaccin
diagnost
recent
studi
show
pattern
direct
conjug
ligand
includ
nucleic
acid
protein
attach
vlp
surfac
addit
superior
access
cystein
lysin
residu
vlp
bioconjug
perform
commerci
homoor
heterobifunct
linker
exampl
three
foreign
protein
chemic
conjug
vlp
surfac
cpmv
proper
bifunct
crosslink
hand
research
could
produc
alphaviru
vlp
surround
function
gold
nanoparticl
vlp
also
use
stimul
immun
respons
gener
antitumor
respons
eg
alphavirusbas
viruslik
replicon
particl
vrp
express
variou
melanoma
antigen
interest
first
viralassoci
cancer
vaccin
found
hbv
vlp
hpv
vlp
prevent
hbvassoci
hepatocellular
carcinoma
hcc
hpvassoci
cervic
carcinoma
respect
note
vlp
formul
viral
vaccin
prevent
viral
infect
may
progress
carcinoma
long
time
indic
applic
vlp
viral
diseas
follow
sever
studi
specif
vaccin
antigen
gener
variou
express
system
induc
protect
immun
respons
appli
licens
recombin
viral
vaccin
exampl
prevent
vlpbase
vaccin
recent
commerci
worldwid
includ
glaxosmithklin
engerixv
r
hbv
cervarixv
r
hpv
merck
co
inc
recombivax
hbv
r
hbv
gardasilv
r
hpv
vlpbase
vaccin
undergo
preclin
evalu
clinic
trial
includ
parvoviru
influenza
norwalkderiv
vlp
also
differ
chimer
vlp
gener
immunogen
vlp
eukari
otic
express
host
includ
yeast
cerevisia
p
pastori
h
polymorpha
mammalian
cell
chines
hamster
ovari
cell
line
cho
use
studi
indic
recombin
hbsag
gener
cho
h
polymorpha
signific
differ
size
molecular
weight
mw
monom
number
furthermor
choderiv
virallik
particl
includ
combin
glycosyl
nonglycosyl
hbsag
protein
similar
patient
sera
yeastderiv
antigen
report
nonglycosyl
chobas
vaccin
provid
pasteurm
erieux
aventi
franc
genhevac
bv
r
scigen
israel
scibvac
tm
vaccin
contain
hbsag
pro
tein
also
protein
genhevac
b
l
protein
scibvac
hand
gardasil
approv
fda
quadri
valent
hpv
type
vlp
vaccin
produc
cerevisia
cervarix
licens
hpv
vaccin
approv
fda
cervarix
bival
hpv
type
vlp
vaccin
express
via
recombin
baculoviru
vector
differ
experi
concentr
hpv
vlp
vaccin
mous
human
model
includ
activ
immatur
human
dc
chimer
vlp
b
determin
system
cytokin
pattern
elicit
hpv
vlp
c
identif
gene
express
signatur
vlpinduc
human
pbmc
gener
potent
prolong
neutral
antibodi
use
singl
intramuscular
im
mice
inject
recombin
adenoassoci
viru
encod
protein
e
augment
immunogen
hpv
dna
vaccin
use
genet
linkag
chemokin
secretori
signal
peptid
sequenc
f
potent
stimul
system
mucos
immun
respons
vlp
vaccin
use
encapsul
genet
cytokin
adjuv
eg
g
improv
vlp
immunogen
linkag
modifi
adjuv
nasal
immun
mice
vlp
chimer
viruslik
particl
cvlp
could
induc
ctl
therapeut
potenti
cvlp
also
indic
consider
safeti
high
grade
cervic
intraepitheli
neoplasia
patient
cin
sever
improv
vaccin
design
vlp
still
preclin
trial
main
exampl
refer
follow
coinject
vlp
e
coli
heatlabil
enterotoxin
lt
adjuv
significantli
increas
level
serum
igg
vagin
iga
nasal
bronchial
mice
immun
antigen
ty
vlp
also
immunogen
welltoler
phase
clinic
trial
g
sever
group
focus
improv
bacteriophagebas
vlp
vaccin
eg
rna
bacteriophag
qb
chimer
vlp
vaccin
target
noninfecti
diorder
includ
hypertens
allergi
neurodegen
autoimmun
diseas
eg
diabet
mellitu
type
ii
alzheim
cancer
eg
melanoma
vaccin
candid
alzheim
construct
display
chemic
coupl
amyloid
beta
peptid
deriv
ntermin
b
cell
epitop
ab
protein
surfac
qbcp
vlp
vaccin
could
stimul
abspecif
igg
decreas
amyloid
accumul
anim
model
express
ab
precursor
protein
without
elicit
tcell
inflammatori
reaction
brain
tissu
addit
angiotensin
ii
vaccin
synthes
coval
conjug
peptid
deriv
angiotensin
ii
rna
bacteriophag
qb
vlp
capsid
modifi
vlp
could
decreas
blood
pressur
spontan
hypertens
rat
tabl
show
preclin
clinic
studi
vlp
vaccin
develop
gener
major
applic
vlp
stimul
immun
foreign
protein
epitop
genet
fuse
chemic
conjug
vlp
entitl
chimer
vlp
cvlp
antigen
fuse
vlp
either
coval
noncoval
bond
common
coval
bond
gener
heterobifunct
chemic
crosslink
amin
sulfhydrylreact
arm
instanc
cysteinecontain
antigen
conjug
lysin
residu
vlp
surfac
high
densiti
eg
three
peptid
per
coat
protein
molecul
noncoval
conjug
strategi
contain
use
streptavidin
linker
attach
biotinyl
antigen
vlp
effici
specif
interact
vlp
also
encapsul
variou
materi
dna
kb
protein
antigen
insert
special
exogen
peptid
surfac
loop
produc
vlp
abil
cell
target
moreov
vlp
stimul
innat
immun
natur
adjuv
inde
vlp
may
promis
vaccin
candid
deliv
heterolog
antigen
follow
induct
ctl
without
synthet
adjuv
sever
chimer
vlp
vaccin
enter
clinic
trial
antiinfluenza
vlp
vaccin
hbcag
vlp
display
epitop
influenza
antihiv
ty
vlp
two
antimalaria
vaccin
hbcag
vlp
display
malaria
epitop
nicotineqb
vlp
antiang
ii
qb
vlp
genet
linkag
contain
stabl
bond
vlp
antigen
studi
show
peptid
shorter
amino
acid
small
peptid
present
without
interf
correct
assembl
vlp
limit
contain
improp
fold
display
antigen
format
cvlp
heterogen
size
prevent
issu
eg
assembl
problem
structur
studi
identifi
domain
differ
vlp
hbcag
hbsag
hiv
gag
necessari
vlp
assembl
well
allow
insert
foreign
antigen
simplest
way
gener
singl
compon
cvlp
insert
peptid
ctermin
region
chimer
vlp
multipl
fusion
posit
identifi
produc
multicompon
cvlp
induc
broad
immun
respons
direct
intens
immun
respons
significantli
influenc
vlp
type
foreign
antigen
densiti
access
within
vlp
furthermor
preexist
immun
epitop
vlp
deliveri
system
may
importantli
chang
respons
heterogen
antigen
exampl
hbcag
also
util
display
neutral
epitop
protein
nasal
deliveri
epitop
cvlp
express
tobacco
induc
antigenspecif
antibodi
respons
mous
model
hand
chimer
vlp
gener
transgen
tomato
present
sever
tcell
epitop
protein
hpv
vlp
elicit
neutral
antibodi
respons
similar
equal
amount
commerci
vaccin
gardasil
preclin
studi
moreov
chimer
vlp
induc
ctl
respons
epitop
chimer
hpv
vlp
also
design
use
genet
fusion
display
epitop
influenza
protein
overcom
problem
associ
genet
fusion
includ
antigen
size
conform
vlp
assembl
differ
applic
viruslik
particl
chemic
conjug
approach
appli
construct
cvlp
strategi
target
antigen
nativ
vlp
gener
individu
coupl
togeth
attach
antigen
surfac
preassembl
vlp
two
main
advantag
strategi
includ
variou
size
type
antigen
expos
b
antigenvlp
bind
site
manipul
present
conjug
antigen
exampl
vlp
use
display
fulllength
correctli
fold
protein
gener
vlp
use
deliveri
proteinpeptid
dna
sirna
drug
brief
descript
follow
virallik
particl
use
peptideprotein
carrier
vitro
vivo
sever
exampl
deliveri
proteinpeptid
use
vlp
follow
chimer
vlp
vaccin
improv
base
rna
bacteriophag
present
peptid
selfantigen
pathogen
fuse
either
ctermin
region
coat
protein
vlp
highli
immunogen
mice
furthermor
influenza
vlp
stimul
effici
antibodi
respons
full
protect
lethal
influenza
viru
challeng
b
vlp
contain
ligand
flvlp
dc
growth
factor
could
effect
increas
immunogen
mice
dc
expos
vlp
also
produc
high
level
c
plant
vlpbase
approach
use
develop
respiratori
syncyti
viru
rsv
vaccin
target
peptid
display
amino
acid
rsv
g
protein
deliv
surfac
recombin
alfalfa
mosaic
viru
almv
particl
construct
induc
high
pathogenspecif
immun
respons
immun
anim
recent
studi
peptid
extern
loop
mous
protein
insert
neutral
epitop
hpv
particl
gener
chimer
could
elicit
high
level
antibodi
specif
recogn
surfac
cell
block
vitro
infect
mtropic
hiv
strain
mice
addit
chimer
vlp
contain
full
length
oncoprotein
link
ntermin
region
fuse
could
induc
antigenspecif
protect
mice
lethal
challeng
tumor
cell
e
epitop
hbv
also
insert
ef
loop
hpv
vlp
recogn
hbvspecif
antibodi
chimer
vlp
produc
ecoli
carri
virusneutr
hbv
epitop
major
immunodomin
region
mir
highli
conserv
ntermin
hcv
core
epitop
aa
ctermin
region
truncat
hbv
core
vlp
hbc
presenc
two
differ
foreign
epitop
within
hbc
molecul
interfer
vlpform
potenti
hbv
epitop
expos
surfac
hcv
core
epitop
buri
within
vlp
mice
vaccin
show
specif
cell
activ
foreign
epitop
highlevel
antibodi
respons
epitop
wherea
antibodi
respons
hbc
carrier
inhibit
f
research
shown
nanos
hbcvlp
bear
mycobacteri
antigen
hbcvlp
fusion
protein
induc
increas
immun
respons
balbc
mice
compar
mixtur
nativ
antigen
g
chimer
papillomaviru
vlp
base
bovin
papillomaviru
type
protein
design
replac
amino
acid
major
protein
synthet
polytop
minigen
contain
known
ctl
epitop
human
protein
hiv
iiib
nef
revers
transcriptas
rt
protein
linear
b
epitop
chimer
protein
assembl
vlp
insect
cell
polytop
vlp
could
deliv
multipl
b
epitop
immunogen
mhc
class
class
ii
pathway
studi
demonstr
hybrid
vlp
use
effici
antigen
deliveri
system
transfer
one
ctl
epitop
mhc
class
pathway
h
chimer
hpv
vlp
gener
neutral
epitop
residu
insert
within
immunodomin
surfac
loop
residu
major
capsid
protein
immun
rabbit
assembl
particl
elicit
high
serum
antibodi
respons
l
studi
show
ctermin
region
gag
fuse
cell
epitop
human
cytomegaloviru
led
format
hybrid
vlp
activ
antigenspecif
memori
cell
ex
vivo
regard
previou
studi
gag
polyprotein
retrovir
protein
requir
vlp
format
vlp
deriv
avian
retroviru
appli
deliv
protein
cell
either
part
gag
fusion
protein
intracellular
deliveri
surfac
vlp
construct
effect
system
vlp
complet
made
gag
fusion
protein
singl
vlp
deliv
copi
gag
fusion
protein
transduc
cell
deliveri
foreign
gene
digest
tract
mucosa
oral
administr
nonrepl
gene
transfer
vector
would
use
method
vaccin
gene
therapi
studi
indic
plasmid
dna
could
packag
vitro
vlp
compos
open
read
frame
hev
oral
transmiss
viru
vlp
could
deliv
foreign
dna
intestin
mucosa
vivo
elicit
high
mucos
system
immun
mice
without
use
adjuv
oral
administ
hiv
dna
vaccin
encapsul
hevvlp
could
induc
mucos
system
cellular
humor
immun
respons
moreov
abil
hpv
vlp
examin
mediat
deliveri
express
dna
plasmid
vitro
vivo
hpv
pseudovirus
provid
disrupt
hpvvlp
mix
dna
plasmid
reassembl
pseudovirus
vlp
plasmid
insid
pseudoviru
induc
potent
immun
respons
dna
vaccin
pseudoviru
could
use
gene
therapi
transfer
therapeut
gene
lymphoid
tissu
human
addit
recombin
vlp
produc
insect
cell
could
effici
encapsul
plasmid
harbor
either
gene
gfp
bgalactosidas
vitro
disassemblyreassembl
vlp
vlpmediat
deliveri
gfp
report
construct
vitro
show
highli
depend
presenc
fulllength
protein
within
vlp
similarli
express
gfp
luciferas
report
plasmid
vivo
effici
enhanc
coadministr
vlp
addit
coadministr
vlp
plasmid
increas
significantli
cellular
immun
respons
report
indic
recombin
major
structur
protein
bk
polyomaviru
bkv
shown
selfassembl
vlp
diamet
nm
potenti
bkv
vlp
investig
transfer
gene
cell
use
three
method
format
pseudovirion
disassemblyreassembl
osmot
shock
direct
interact
vlp
plasmid
dna
effici
method
direct
interact
vlp
linear
plasmid
dna
find
gener
demonstr
bkv
vlp
exogen
dnabind
activ
promis
vehicl
gene
transfer
studi
sirna
deliveri
major
challeng
identifi
novel
approach
specif
effect
deliveri
new
type
drug
like
sirna
peptid
system
deliveri
small
interf
rna
sirna
restrict
poor
stabil
low
cellpenetr
properti
overcom
limit
effici
sirna
deliveri
system
design
use
polyethyleneimin
pei
coat
vlp
deriv
adenoassoci
viru
type
gener
one
strategi
integr
sirna
nanoparticl
coat
particl
posit
charg
polym
includ
pei
poli
bamino
differ
applic
viruslik
particl
ester
poli
llysin
electrostat
coat
could
increas
effici
system
sirna
deliveri
due
protect
effect
improv
cellular
uptak
insectbaculoviru
express
system
use
gener
could
condens
sirna
protect
enzymat
degrad
transfer
high
effici
induc
cell
death
breast
cancer
cell
breast
cancer
therapi
furthermor
microrna
mirna
play
essenti
role
immunoregul
may
involv
pathogen
esi
system
lupu
erythematosu
sle
among
slerel
mirna
act
signific
inhibitor
autoimmun
myeloprolifer
cancer
novel
mirnadeliveri
approach
describ
via
bacteriophag
vlp
evalu
therapeut
effect
bxsb
lupuspron
mice
treatment
vlp
increas
level
matur
lead
signific
reduct
express
autoantibodi
total
igg
furthermor
level
inflammatori
cytokin
includ
ifna
decreas
mice
stimul
dysregul
mirna
vlpbase
deliveri
system
may
consid
novel
therapi
use
vlp
report
select
deliveri
nanoparticl
chemotherapeut
drug
sirna
cocktail
protein
toxin
human
hcc
addit
research
use
jc
viru
jcv
vlp
vector
deliv
rnai
silenc
cytokin
gene
jcv
vlp
nontox
show
therapeut
use
gene
therapi
approach
autoimmun
diseas
aid
includ
sle
drug
deliveri
major
challeng
pharmacolog
find
method
drug
especi
anticanc
drug
deliv
specif
target
tissu
potenti
strategi
would
packag
encapsul
drug
molecul
insid
particl
bound
cancer
tissu
encapsul
would
protect
drug
degrad
blood
purpos
necessari
develop
particl
modifi
outer
surfac
carri
drug
molecul
target
cell
novel
nanocarri
dendrim
liposom
polymersom
micel
vlp
indic
high
potenc
improv
drug
deliveri
target
strategi
deliveri
system
make
drug
biocompat
watersolubl
colloid
indic
low
toxic
high
uptak
cell
differ
virusbas
materi
studi
drug
deliveri
ccmv
cpmv
red
clover
necrot
mosaic
viru
rcnmv
rnacontain
bacteriophag
bacteriophag
qb
bacteriophag
tmv
drug
cargo
load
coval
attach
drug
analog
particular
reactiv
residu
capsid
protein
sever
cancer
cell
target
ligand
attach
differ
type
vlp
includ
small
molecul
antibodi
peptid
protein
well
dna
aptam
folic
acid
fa
broadli
use
drug
deliveri
target
cancer
cell
uptak
fa
cell
mediat
folat
receptor
fr
recent
lactobion
acid
la
appli
specif
target
rotaviru
capsid
hepatocyt
hepatoma
cell
bear
asialoglycoprotein
receptor
asgpr
human
holotransferrin
tfn
essenti
iron
homeostasi
tfn
especi
recogn
tfn
receptor
tfnr
overexpress
surfac
variou
tumor
cell
effici
taken
cell
clathrinmedi
endocytosi
tfn
conjug
cpmv
bacteriophag
qb
cellular
uptak
qbtfn
particl
rel
tfn
densiti
intern
prevent
compar
concentr
free
tfn
antibodi
contain
anoth
group
target
protein
could
chemic
link
vlp
instanc
singlechain
scfv
antibodi
recogn
carcinoembryon
antigen
cea
overexpress
varieti
tumor
cell
attach
cpmv
import
strategi
improv
cellular
uptak
therapeut
molecul
use
cellpenetr
peptid
cpp
tat
peptid
one
cpp
extens
use
deliveri
vlp
gener
viruslik
particl
repres
attract
system
drug
deliveri
vitro
effici
deliveri
hydrophob
drug
target
cell
without
use
organ
solvent
chemic
linkag
deliveri
carrier
critic
issu
biolog
field
recent
intracellular
deliveri
hydrophob
dye
drug
encapsul
vlp
cyclodextrin
cd
show
high
effici
model
anticanc
drug
paclitaxel
ptx
cd
complex
encapsul
insid
vlp
exhibit
dosedepend
cytotox
effect
smaller
free
ptx
dissolv
dmso
cell
target
aim
effect
uptak
therapeut
diagnost
reagent
special
locat
tumor
target
also
achiev
use
protein
mainli
antibodi
peptid
nucleic
acid
aptam
small
molecul
vitamin
carbohydr
attach
target
ligand
specif
cell
target
obtain
receptormedi
endocytosi
instanc
bacteriophag
vlp
chemic
conjug
target
peptid
select
deliveri
nanoparticl
chemotherapeut
drug
sirna
cocktail
protein
toxin
human
hcc
recent
chemic
conjug
human
epiderm
growth
factor
egf
simian
viru
vlp
allow
cell
shirbaghae
bolhassani
select
target
simian
virus
vlp
attract
great
attent
gene
deliveri
due
high
stabil
low
toxic
blood
design
polymer
nanoassembl
chemic
modif
necessari
conjug
dye
probe
vitro
vivo
imag
howev
case
nanobioassembl
chemic
genet
modif
appli
bioconjug
fluoresc
dye
probe
anoth
advantag
nanobioassembl
vlp
bioimag
biolog
compat
quantum
dot
qd
gfp
use
broadli
vitro
vivo
imag
altern
label
exampl
fluoresc
chimer
vlp
canin
parvoviru
express
insect
cell
creat
fluoresc
chimer
vlp
canin
parvoviru
gfp
genet
engin
onto
ntermin
region
viral
protein
visual
tool
understand
mechan
viral
infect
gfp
also
use
design
chimer
hiv
vlp
allow
protein
follow
assembl
transmiss
use
livecel
imag
advantag
vlp
includ
need
propag
pathogen
organ
b
repetit
order
surfac
structur
c
multival
well
particul
natur
safer
vaccin
noninfecti
nonrepl
properti
studi
show
risk
diseas
progress
vaccin
group
vlpbase
vaccin
compar
attenu
viral
vaccin
lack
genom
materi
need
replic
spread
virus
e
stabl
extrem
environment
condit
depend
vlp
structur
ie
envelop
nonenvelop
f
carrier
express
foreign
antigen
potenti
vlp
target
dc
main
advantag
vlp
vaccin
activ
innat
adapt
immun
respons
special
benefit
deliveri
system
size
stabil
capac
transfer
biolog
molecul
across
cell
barrier
particl
nm
rang
stimul
cell
especi
gener
respons
addit
despit
limit
number
vlp
vaccin
approv
human
use
repres
promis
platform
develop
novel
mucos
vaccin
strategi
inde
vlp
suffici
small
composit
surfac
chemistri
design
minim
hydrophob
electrostat
adhes
interact
mucu
also
engin
recombin
express
multipl
antigen
epitop
incorpor
costimulatori
immunoregulatori
protein
howev
vlp
technolog
limit
difficulti
scaleup
need
purif
express
system
limit
chimer
vlp
vaccin
determin
compat
peptid
assembl
vlp
immunogen
properti
host
immun
defenc
pathogen
undergo
mutat
render
vlp
vaccin
ineffect
effect
highli
conserv
b
cell
epitop
major
challeng
develop
novel
product
platform
deliv
vlp
vaccin
significantli
reduc
product
time
cost
virallik
particl
vlp
shown
high
abil
improv
vaccin
infecti
noninfecti
diseas
sever
recombin
express
system
success
appli
vlp
product
differ
effici
use
vlp
vaccin
develop
show
consid
safe
addit
nanos
vlp
act
adjuv
well
antigen
deliveri
system
increas
antigen
uptak
apc
thu
necessari
use
adjuv
along
vlp
stimul
potent
immun
respons
vlp
shown
natur
affin
target
host
cell
properti
use
celltarget
applic
regard
advantag
vlp
necessari
studi
variou
aspect
especi
easi
lowcost
purif
vlp
well
applic
deliveri
system
vivo
